Pesquisar
TG Therapeutics Inc
TGTXAdicionar à lista de desejos
55.900USD
+0.180+0.32%
Horário de mercado （ET）Cotações atrasadas em 15 min
8.56BValor de mercado
17.46P/L TTM
Mais detalhes de TG Therapeutics Inc Empresa
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
Informações de TG Therapeutics Inc
Código da empresaTGTX
Nome da EmpresaTG Therapeutics Inc
Data de listagemDec 14, 1995
CEOWeiss (Michael S)
Número de funcionários338
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 14
Endereço3020 Carrington Mill Blvd., Suite 475
CidadeMORRISVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal27560-5435
Telefone18775758489
Sitehttps://www.tgtherapeutics.com/
Código da empresaTGTX
Data de listagemDec 14, 1995
CEOWeiss (Michael S)
Executivos da empresa TG Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.78M
--
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
690.61K
--
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
--
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
223.82K
--
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
--
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
179.69K
--
Dr. Sagar Lonial
Dr. Sagar Lonial
Independent Director
Independent Director
94.06K
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.78M
--
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
690.61K
--
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
--
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
223.82K
--
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
--
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
179.69K
--
Perguntas frequentes
Quem são os cinco principais acionistas de TG Therapeutics Inc?
Os cinco principais acionistas de TG Therapeutics Inc são: Mr. Michael S. Weiss, J.D.
Quantas instituições possuem ações da TG Therapeutics Inc (TGTX)?
Em 2026Q1, 760 instituições possuíam ações da TG Therapeutics Inc, com valor de mercado aproximado de 122.50M, representando 80.02% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 4398281.00.
Qual é a maior fonte de receita da TG Therapeutics Inc?
Em 2026Q1, o segmento de negócios Total product revenue, net gerou a maior receita para TG Therapeutics Inc, totalizando 606.93M e representando 98.48% da receita total.
